Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Ethris GmbH secures €30M financing under HERA Invest to advance clinical development of respiratory mRNA products. This funding will support the progression of their lead candidate, ETH47, into Phase 2 trials.

PRIVATESep 10, 2026•about 3 hours ago

Amount Raised

€30 Million

Round Type

Venture - Series Unknown

MunichBiotechnologyHealth CareTherapeutics

Investors

European Investment Bank

Description

Ethris GmbH has announced a €30 million financing agreement with the European Investment Bank under HERA Invest. The funding will be used to advance clinical development of Ethris’ portfolio of respiratory mRNA products, including their lead candidate ETH47. The financing will support the transition of ETH47 into Phase 2b trials in patients with asthma and COPD. This financing will enable the company to further demonstrate the potential of their novel antiviral approach.

Company Information

Company

Ethris GmbH

Location

Munich, Bavaria, Germany

About

Ethris is a clinical-stage biotechnology company that specializes in next-generation RNA therapeutics and vaccines. The company has developed innovative therapies using proprietary RNA and lipidoid nanoparticle technology platforms. With over a decade of experience as an mRNA pioneer, Ethris focuses on delivering stabilized mRNAs directly to the respiratory system. Their lead candidate, ETH47, aims to address respiratory conditions such as uncontrolled asthma.

Don't miss Ethris GmbH's next move

Get an email the moment Ethris GmbH raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Ethris GmbH's next move

See what Strategic adds

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Ethris GmbH raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.